FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--ImmunSYS, Inc., a clinical stage biotechnology company focused on the development of YourVaccx™, a new intratumoral immunotherapy system for metastatic castrate resistant prostate cancer and other solid tumor cancers, announced today that the company received the top award at the recent BioPitch 2019, a Shark Tank for life science companies that highlighted the 2019 BioFlorida annual conference.
The company won $10,000 after besting 15 other seed-stage and early-stage life science firms that also pitched at the Oct. 22 conference in Tampa. More than 20 investor judges worked over the past several months to review a record-breaking number of applications for BioPitch, and they determined the 16 semi-finalists who presented at the conference, said Jane Teague, who organized the pitch competition and is executive director of the Institute for Commercialization of Florida Technology.
In addition to the pitch competition, the conference featured biotech leaders presenting research updates, and panels discussing the state of the industry in Florida.
To learn more about ImmunSYS and BioPitch 2019, you can read the recap here: https://stpetecatalyst.com/meet-the-company-that-won-10000-at-biopitch
ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other adenocarcinomas. The company’s platform technology, YourVaccx™ utilizes a novel combination of the ANTIGENerator™ energy delivery system and a proprietary formulation of immunotherapeutic drugs.
This new immunotherapy therapy is designed to empower the immune system to recognize and selectively attack cancer cells. The company is initially developing the new cancer therapy for the treatment of metastatic prostate cancer, with a pipeline of additional development programs for other cancers. For more information about the company and its programs, visit http://www.immunsys.com/.
This news release contains forward-looking statements. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and other words and terms of similar meaning. The forward-looking statements contained in this news release include, but are not limited to, statements relating to future clinical results and the effectiveness of the company’s therapies. These forward-looking statements are subject to risks, uncertainties and other factors. Accordingly, actual results may differ significantly from those projected in the forward-looking statements contained herein. Readers should not place undue reliance on these forward-looking statements. The forward-looking statements included in this new release are made only as of the date hereof, and the company does not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.